Companies: 10,795·Total market cap: $144.5T
IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc.

IDYANASDAQHealthcare● Active
$30.83
+$2.54(+8.96%)
Market Cap$2.7B
P/E Ratio
52W High$39.28
52W Low$20.455
Overview

IDEAYA Biosciences, Inc. (IDYA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

idya · stock forecast · 25 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 25 Wall Street analysts in the past 3 months

SellBuy

Buy

25 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
23
Hold
2
Sell
0
Strong Sell
0
Total: 25 · Buy rate: 92.0%

12-Month Price Target

High

$65.00

Consensus

$58.67

+99.7% upside

Low

$53.00

Median: $58 · Last Close: $29.38

The IDEAYA Biosciences, Inc. (IDYA) analyst consensus is Buy, based on ratings from 25 Wall Street analysts over the past 3 months. The average 12-month IDYA price target is $58.67, representing +99.7% upside from the current price of $29.38.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $59 (99.7%)

Consensus Target

$58.67

99.7% upside

High Target

$65

121.2%

Low Target

$53

80.4%

Current Price

$29.38

as of today

Based on analyst price targets, the IDYA stock price prediction for the next 12 months ranges from $53 to $65. The consensus IDYA price forecast of $58.67 implies 99.7% upside from the current price of $29.38.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$29.210.58%

1-day model range: $29.09–$29.33. Peak: $29.33 (-0.58%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$32+9.9%
2028$34+16.4%
2029$35+20.6%
2030$36+23.2%
2031+24.8%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

NEUTRAL

Based on 14 technical indicators

43%7%50%
6Buy
1Neutral
7Sell
RSI (14)57.2Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · IDYA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$28.63BUY
MA 10$28.95BUY
MA 20$28.83BUY
MA 50$30.04SELL
MA 100$31.64SELL
MA 200$31.02SELL
Current $IDYA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$28.89BUY
EMA 10$28.89BUY
EMA 20$29.02BUY
EMA 50$29.91SELL
EMA 100$30.67SELL
EMA 200$30.19SELL
Current $IDYA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Wedbush2026-06-02
Maintains
OutperformOutperform
Mizuho2026-05-07
Maintains
OutperformOutperform
Wells Fargo2026-04-14
Maintains
OverweightOverweight
Goldman Sachs2026-04-14
Maintains
NeutralNeutral
Guggenheim2026-04-14
Maintains
BuyBuy
Wedbush2026-04-14
Maintains
OutperformOutperform
RBC Capital2026-04-14
Maintains
OutperformOutperform
Wedbush2026-03-31
Maintains
OutperformOutperform
Citigroup2026-02-19
Maintains
BuyBuy
RBC Capital2026-02-18
Maintains
OutperformOutperform

Wall Street analysts have recently issued updated ratings on IDEAYA Biosciences, Inc. (IDYA) stock. Of the recent 102 rating actions, 3 were upgrades and 2 were downgrades. 25 analysts currently cover IDYA.

Analyst Recommendation Trends

Buy ratings211
Hold ratings00
Sell ratings00

IDYA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$35M

↓ 86.7% YoY

Revenue Next Year

$117M

↑ 236.1% YoY

EPS This Year

$-4.39

EPS Next Year

$-3.79

↓ 13.5% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast IDYA EPS of $-4.39 for the current fiscal year, based on estimates from 13 analysts. The IDYA revenue forecast is $35M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The IDYA stock forecast is supported by two independent data sources: analyst consensus ratings from 25 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IDYA price target is $58.67 (+99.7% upside), with an analyst consensus of Buy.

The IDYA short-term stock prediction for tomorrow is $29.21 (-0.58%). The IDYA stock price prediction for 2027 estimates an average of $32. The IDYA stock prediction for 2030 projects a range of $35–$38.

IDEAYA Biosciences, Inc. trades on NASDAQ under the ticker IDYA. The IDYA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 92% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

IDYA forecast · 8 questions

According to 25 Wall Street analysts, the average 12-month IDYA price target is $58.67, with a high forecast of $65.00 and a low of $53.00. The median price target is shown in the chart above when available. This implies +99.7% potential upside from the current price of $29.38.

IDYA price targetWhat is IDYA price targetIDYA analyst price targetIDYA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.